Siegfried-CEO: Investitionen in Abfüllanlage für BioNTech lohnen sich – Siegfried-Aktie im Plus

Der Pharmazulieferer Siegfried muss für die Abfüllung des COVID-19-Impfstoffes der deutschen Biontech eine neue Anlage bauen …
(Orginal – Story lesen…)

This website stores some user agent data. These data are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to opt-out of any future tracking, a cookie will be set up in your browser to remember this choice for one year. I Agree, Deny
700